Entero Therapeutics, Inc. Overview
Pro stress-test →Entero Therapeutics is a publicly listed company that combines a late clinical-stage biopharmaceutical business with a growing focus on AI-driven energy and digital infrastructure, having acquired Grid AI Corp to operate a grid-edge software and controls platform for AI data centers, utilities, and large power users. The company develops Adrulipase, a recombinant lipase enzyme designed to enable fat digestion in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.
Strategic Profile
Pro stress-test →The company will rebrand to GridAI Technologies Corp. and change its ticker to GRDX, effective December 1, 2025, reflecting its pivot toward the AI energy-infrastructure market. Following the Grid AI acquisition, Entero intends to continue its GI drug development while operating Grid AI as a wholly owned subsidiary.
Competitive Landscape
Pro stress-test →Grid AI's platform leverages IoT, AI/ML and edge analytics to forecast, optimize and dispatch flexible demand across millions of devices for utilities, retailers and large energy users. Direct competitors in grid-edge AI/DER aggregation include Fluence, Stem, and distributed energy orchestration vendors. The biotech division faces competition from other GI enzyme replacement therapies and digestive disorder treatments. The company's transition toward AI infrastructure positions it against established cloud platforms and emerging energy software vendors.
Industry Context
Entero Therapeutics, Inc. operates in Grid-edge AI and energy orchestration software.
Key facts
Founded: N/A · Headquarters: Boca Raton, US · Employees: N/A · Revenue: N/A · Market cap: N/A